ASCO GU 2017: Year in Review - Session Highlights
Orlando, Florida USA (UroToday.com) Dr. James Catto, Editor in Chief of European Urology presents a review of the most important publications in the field of prostate cancer in 2016. The field of prostate cancer has seen a significant number of advances in the last years ranging from advances in imaging, biopsy technique, the radical treatment of oligometastatic disease and the use of docetaxel in the management of hormone sensitive metastatic prostate cancer along others.
ASCO GU 2017: Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease. - Poster Session Highlights
Orlando, Florida USA (UroToday.com) This study is the first meta-analysis of the performance of the Decipher genomic classifier in prostate cancer patients post-RP.
ASCO GU 2017: Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP). - Poster Session Highlights
Orlando, Florida USA (UroToday.com) As Radium-223 is not approved for asymptomatic metastatic castration-resistant prostate cancer (mCRPC), this group of investigators sought to define the added benefit by employing the alpha targeting therapy earlier on in the disease course.
ASCO GU 2017: A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. - Poster Session Highlights
Orlando, Florida USA (UroToday.com) This study by Neal Shore et al examined the feasibility and safety of a novel DNA-based immunotherapy called INO-5150 in a cohort of patients with biochemically relapsed prostate cancer.
ASCO GU 2017: Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial. - Poster Session Highlights
Orlando, Florida USA (UroToday.com) Nabid et al from Canada reported a secondary analysis from NCT00223145 investigating the ability of testosterone level after short term androgen deprivation therapy (ADT) to prognosticate prostate cancer outcomes after combined ADT and radiation.
ASCO GU 2017: Can focal therapy impact perioperative, oncological, and functional outcomes in men who underwent focal therapy salvage robotic-assisted radical prostatectomy? A retrospective matched-pair comparative study. - Poster Session Highlights
Orlando, Florida USA (UroToday.com) This multinational study sought to identify the differences in outcomes subsequent to salvage robotic assisted radical prostatectomy (RARP) vs. RARP in treatment naïve patients.
ASCO GU 2017: Twitter mentions and academic citations in the urologic oncology literature. - Poster Session Highlights
Orlando, Florida USA (UroToday.com) Social media has been aggressively adopted by clinicians and scientists in exchanging research findings and new ideas for scientific investigations.